These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33860404)

  • 21. Pandemic Vaccines: How Are We Going to Be Better Prepared Next Time?
    Krammer F
    Med; 2020 Dec; 1(1):28-32. PubMed ID: 33521752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International COVID-19 vaccine inequality amid the pandemic: Perpetuating a global crisis?
    Tatar M; Shoorekchali JM; Faraji MR; Wilson FA
    J Glob Health; 2021 Jul; 11():03086. PubMed ID: 34221356
    [No Abstract]   [Full Text] [Related]  

  • 23. COVID-19 vaccines: the pandemic will not end overnight.
    The Lancet Microbe
    Lancet Microbe; 2021 Jan; 2(1):e1. PubMed ID: 33521732
    [No Abstract]   [Full Text] [Related]  

  • 24. Cancer and COVID-19 vaccines: a complex global picture.
    Yusuf A; Sarfati D; Booth CM; Pramesh CS; Lombe D; Aggarwal A; Bhoo-Pathy N; Tsunoda A; Vanderpuye V; Kutluk T; Sullivan A; Mukherji D; Mutebi M; van Hemelrijck M; Sullivan R;
    Lancet Oncol; 2021 Jun; 22(6):749-751. PubMed ID: 33930324
    [No Abstract]   [Full Text] [Related]  

  • 25. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ensuring equitable access to vaccines for refugees and migrants during the COVID-19 pandemic.
    Bartovic J; Datta SS; Severoni S; D'Anna V
    Bull World Health Organ; 2021 Jan; 99(1):3-3A. PubMed ID: 33658728
    [No Abstract]   [Full Text] [Related]  

  • 27. [Monoclonal antibodies for anti-infective therapy].
    Klug B; Schnierle B; Trebesch I
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1396-1402. PubMed ID: 33034695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy.
    Novelli G; Biancolella M; Mehrian-Shai R; Colona VL; Brito AF; Grubaugh ND; Vasiliou V; Luzzatto L; Reichardt JKV
    Hum Genomics; 2021 May; 15(1):27. PubMed ID: 33966626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.
    Frieman M; Harris AD; Herati RS; Krammer F; Mantovani A; Rescigno M; Sajadi MM; Simon V
    EBioMedicine; 2021 Jun; 68():103401. PubMed ID: 34051441
    [No Abstract]   [Full Text] [Related]  

  • 31. The evolution of clinical trials in response to COVID-19.
    Sarah A; Dean O; Berk M
    Med J Aust; 2021 Apr; 214(7):332-332.e1. PubMed ID: 33749864
    [No Abstract]   [Full Text] [Related]  

  • 32. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19: The Need for Immunoprevention at Industrial Scale.
    Halstead SB
    Am J Trop Med Hyg; 2020 Jun; 102(6):1151. PubMed ID: 32274985
    [No Abstract]   [Full Text] [Related]  

  • 34. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.
    Hansel K; Zangrilli A; Bianchi L; Peris K; Chiricozzi A; Offidani A; Diotallevi F; Fargnoli MC; Esposito M; Amerio P; Gualdi G; Bianchi L; Stingeni L
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):e169-e170. PubMed ID: 33080112
    [No Abstract]   [Full Text] [Related]  

  • 35. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.
    Moore JP; Offit PA
    JAMA; 2021 Mar; 325(9):821-822. PubMed ID: 33507218
    [No Abstract]   [Full Text] [Related]  

  • 36. COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view.
    Vitiello A; Porta R; Pianesi L; Ferrara F
    Ir J Med Sci; 2022 Feb; 191(1):487-488. PubMed ID: 33710481
    [No Abstract]   [Full Text] [Related]  

  • 37. COVID-19 in Latin America-emergency and opportunity.
    The Lancet
    Lancet; 2021 Jul; 398(10295):93. PubMed ID: 34246349
    [No Abstract]   [Full Text] [Related]  

  • 38. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?
    Saad Albichr I; De Greef J; Van Den Neste E; Poiré X; Havelange V; Vekemans MC; Bailly S; Yombi JC; Mzougui S; Scohy A; Kabamba-Mukadi B
    Leuk Lymphoma; 2022 Mar; 63(3):743-746. PubMed ID: 34706604
    [No Abstract]   [Full Text] [Related]  

  • 39. COVID-19 vaccines and treatments: When speed is necessary and not enough.
    Grasela TH; Price DA; Wagner JA
    Clin Transl Sci; 2021 Jul; 14(4):1201-1205. PubMed ID: 33834614
    [No Abstract]   [Full Text] [Related]  

  • 40. The challenges with developing therapeutic monoclonal antibodies for pandemic application.
    Laustsen AH; Bohn MF; Ljungars A
    Expert Opin Drug Discov; 2022 Jan; 17(1):5-8. PubMed ID: 34503379
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.